Table 1.
Baseline characteristics
| GROUP | ||||
|---|---|---|---|---|
|
| ||||
| Total | Viremic | Suppressed | ||
| N = 35 | N = 12 | N = 23 | ||
| Age | Min, Max | 24, 66 | 24, 58 | 26, 66 |
| Median (Q1, Q3) | 50 (44, 54) | 49 (35, 53) | 51 (45, 57) | |
| Sex | M | 28 (80%) | 11 (92%) | 17 (74%) |
| F | 7 (20%) | 1 (8%) | 6 (26%) | |
| Race | African American | 22 (63%) | 10 (83%) | 12 (52%) |
| Caucasian | 12 (34%) | 1 (8%) | 11 (48%) | |
| Hispanic | 1 (3%) | 1 (8%) | 0 (0%) | |
| Nadir CD4 cell count (cells/mm3)* | N | 21 | ||
| Min, Max | 23, 578 | |||
| Median (Q1, Q3) | 227 (89, 314) | |||
| ART Duration at time of screening (years) | <4 | 9 (39%) | ||
| >4 | 11 (48%) | |||
| missing | 3 (13%) | |||
| Pre-ART HIV-1 RNA level (log10 (copies/mL)* | N | 20 | ||
| Min, Max | 3.7, 6.7 | |||
| Median (Q1, Q3) | 5.0 (4.3, 5.1) | |||
| Pre-ART HIV-1 RNA level (copies/mL)* | ≤ 10K | 2 (9%) | ||
| 10K – 100K | 11 (48%) | |||
| ≥ 100K | 7 (30%) | |||
| missing | 3 (13%) | |||
| Screening CD4 cell count (cells/mm3) | N | 35 | 12 | 23 |
| Min, Max | 17, 1,667 | 17, 1,053 | 386, 1,667 | |
| Median (Q1, Q3) | 628 (392, 835) | 240 (102, 810) | 642 (486, 835) | |
| Screening CD4 cell count (%) | N | 33 | 11 | 22 |
| Min, Max | 3, 55 | 3, 45 | 24, 55 | |
| Median (Q1, Q3) | 32 (25, 40) | 17 (8, 31) | 35 (30, 43) | |
*
Data not available for the Viremic group